Coagulation effects of oral contraception

Area of Science:

• Reproductive Health
• Cardiovascular Science
• Hematology

Background:

• Estrogen/progestogen oral contraceptives are linked to increased risks of venous thromboembolism, myocardial infarction, and stroke.
• These risks are heightened in smokers and women over 35.
• Vascular risks correlate with estrogen dosage and both estrogen and progestogen components.

Purpose of the Study:

• To investigate the relationship between oral contraceptive components and coagulation/thrombotic events.
• To understand how estrogen/progestogen formulations affect blood clotting and fibrinolysis.
• To identify formulations that minimize adverse effects on the coagulation system.

Main Methods:

• Review of existing literature on oral contraceptives and thrombotic events.
• Analysis of the effects of estrogen and progestogen on coagulation factors (fibrinogen, factors VII, X) and antithrombin III.
• Assessment of platelet activity and fibrinolytic response.

Main Results:

• Oral contraceptives alter blood clotting by increasing fibrinogen and coagulation factors, while decreasing antithrombin III.
• Platelet aggregation is enhanced, leading to hypercoagulability, partially offset by increased fibrinolysis.
• Coagulation effects are dose-dependent on estrogen and influenced by the progestogen type.

Conclusions:

• Oral contraceptives significantly impact hemostasis, increasing thrombotic risk.
• Formulation-dependent effects necessitate careful selection of estrogen/progestogen combinations.
• Development of low-dose formulations represents a significant advancement in reducing vascular thrombotic risks.